UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 傍神経節腫および褐色細胞腫：悪性疾患のマネージメント paraganglioma and pheochromocytoma management of malignant disease
2. 縦隔腫瘤の評価 evaluation of mediastinal masses
3. シャーガス心臓病：臨床症状および診断 chagas heart disease clinical manifestations and diagnosis

English Journal

Likelihood of bone recurrence in prior sites of metastasis in patients with high-risk neuroblastoma.

Polishchuk AL1, Li R2, Hill-Kayser C3, Little A4, Hawkins RA5, Hamilton J1, Lau M1, Tran HC6, Strahlendorf C7, Lemons RS8, Weinberg V1, Matthay KK9, DuBois SG9, Marcus KJ2, Bagatell R4, Haas-Kogan DA10.
International journal of radiation oncology, biology, physics.Int J Radiat Oncol Biol Phys.2014 Jul 15;89(4):839-45. doi: 10.1016/j.ijrobp.2014.04.004. Epub 2014 May 24.
PURPOSE/OBJECTIVES: Despite recent improvements in outcomes, 40% of children with high-risk neuroblastoma will experience relapse, facing a guarded prognosis for long-term cure. Whether recurrences are at new sites or sites of original disease may guide decision making during initial therapy.METHODS
PMID 24867534

Phase-1 clinical trial results of high-specific-activity carrier-free 123I-iobenguane.

Chin BB1, Kronauge JF, Femia FJ, Chen J, Maresca KP, Hillier S, Petry NA, James OG, Oldan JD, Armor T, Stubbs JB, Stabin MG, Babich JW.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.J Nucl Med.2014 May;55(5):765-71. doi: 10.2967/jnumed.113.124057. Epub 2014 Mar 13.
A first-in-human phase 1 clinical study was performed on 12 healthy adults with a high-specific-activity carrier-free formulation of (123)I-iobenguane. Clinical data are presented on the behavior of this receptor-targeting imaging agent.METHODS: Whole-body and thoracic planar and SPECT imaging were
PMID 24627436

Blue Cross Blue Shield Association, Kaiser Permanente.
Technology Evaluation Center Assessment Program. Executive summary.Technol Eval Cent Assess Program Exec Summ.2014 Apr;28(12):1-3.
PMID 24933741

山科昌平
核医学画像診断 26(1), 49-57, 2011-11-26
… 123I-MIBG（3-iodobenzylguanidine）は心臓交感神経機能を客観的に評価できる検査法で，心不全症例の重症度評価，予後予測，治療効果の評価などに多くの有用な情報を提供する。 …
NAID 120003628214

英: metaiodobenzylguanidine, MIBG, iobenguane
同: 3-ヨードベンジルグアニジン 3-iodobenzylguanidine
関: 放射性医薬品; 131I-メタヨードベンジルグアニジン 131I-MIBG; 123I-メタヨードベンジルグアニジン 123I-MIBG; グアニジン